Pharmaceutical & BioScience Society, PBSS

Symposium

[Free Online Symposium] Advances in Cancer Therapeutics

Speakers: Thorsten Melcher, RefleXion Medical; Erin Filbert, Apexigen; Pina Cardarelli, GPCR Therapeutics; Seema Kantak, Exelixis; Samuel Blackman, Day One Biopharmaceuticals; Holger Wesche, Harpoon Therapeutics Inc.; Mikayel Nazloyan, PricewaterhouseCoopers; James Trager, Nkarta Therapeutics; Kristin Bedard, Sutro Biopharma; Sarah Bodary, AbCellera; Steve Kelsey, Revolution Medicines; Tian Zhao, OncoNano
Organizers: Snow Ge, PhD; Toby Freedman, PhD; Wenfeng Xu, PhD; Donald McCarthy, PhD; Betty Chang, PhD; Joe Carlino, PhD; Peter Staehr, MD; Shichang Miao, PhD
Date: 2022-08-17- 08/18/2022
Time: 8:30-12:30 Pacific Time
Registration fee: 0
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2022-08-16 (it will close sooner if the seating cap is reached)

About the Topic

Note: This is an online meeting, The Zoom link will be sent to the registrants 1+ days before the event.

About the Speakers

James Trager, CSO, Nkarta Therapeutics
Kristin Bedard, VP Discovery, Sutro Biopharma
Pina Cardarelli, CSO, GPCR Therapeutics
Seema Kantak, SVP, Head of Biologics & Biotherapeutics, Exelixis
Samuel Blackman, CMO, Day One Biopharmaceuticals
Erin Filbert, Director of IO, Apexigen
Steve Kelsey, President, Research and Development, Revolution Medicines
Thorsten Melcher, CBO, RefleXion Medical
Mikayel Nazloyan, Partner, PricewaterhouseCoopers
Sarah Bodary, VP Portfolio Innovation and Partnering, AbCellera
Holger Wesche, CSO, Harpoon Therapeutics Inc.
Tian Zhao, VP R&D, OncoNano

August 17th Agenda

Time (PDT)	Time (EST)	Topic	Presenter
8:30-8:45am	11:30-11:45am	Welcome Remarks
8:45-9:20am	11:45-12:20pm	Biology-Guided External-Beam Radiotherapy for All Stages of Cancer	Thorsten Melcher, PhD, CBO, RefleXion Medical
9:20-9:55am	12:20-12:55pm	APX601: a potent TNFR2 antagonist for reversing tumor-mediated immune suppression	Erin Filbert, PhD, Director of IO, Apexigen
9:55-10:30am	12:55-1:30pm	Targeting GPCRs: CXCR4 and ADRB2 for the Treatment of Cancer	Pina Cardarelli, PhD, CSO, GPCR Therapeutics
10:30-10:45am	1:30-1:45pm	Break	--
10:45-11:20am	1:44-2:20pm	Anti-tissue factor ADC. XB002: A novel anti-tissue factor ADC for the treatment of solid tumors	Seema Kantak, PhD, SVP, Head of Biologics & Biotherapeutics, Exelixis
11:20-11:55am	2:20-2:55pm	Clinical Development of Tovorafenib, a pan-RAF Inhibitor, for Relapsed/Progressive Pediatric Low-Grade Glioma	Sam Blackman, MD, PhD, CMO, Day One Biopharmaceutical
11:55-12:30pm	2:55-3:30pm	Novel Approaches to Expand the Therapeutic Index of T cell Engagers	Holger Wesche, PhD, CSO, Harpoon Therapeutics Inc.
12:30-12:50pm	3:30-3:50pm	PANEL DISCUSSION	All speakers

August 18th Agenda

Time (PDT)	Time (EST)	Topic	Presenter
8:30-8:45am	11:30-11:45am	Welcome Remarks
8:45-9:20am	11:45-12:20pm	Financing Trends in Oncology	Mikayel Nazloyan, Partner, PricewaterhouseCoopers
9:20-9:55am	12:20-12:55pm	Progress in the development of CAR NK cell therapies for cancer	James Trager, PhD, CSO, Nkarta, Inc
9:55-10:30am	12:55-1:30pm	Complex Biologics for Cancer Treatment: ADCs and Beyond	Kristin Bedard, PhD, VP Discovery, Sutro Biopharma
10:30-10:45am	1:30-1:45pm	Break	--
10:45-11:20am	1:44-2:20pm	Business Development trends in the dynamic oncology market	Sarah Bodary, PhD, VP Portfolio Innovation and Partnering, AbCellera
11:20-11:55am	2:20-2:55pm	Targeting RAS-addicted cancers with tricomplex RAS(ON) inhibitors	Steve Kelsey, MD, President, Research and Development, Revolution Medicines
11:55-12:30pm	2:55-3:30pm	Tumor specific delivery of therapeutics using a clinically validated ultra pH-sensitive nanoparticle platform	Tian Zhao, Ph.D., VP R&D, OncoNano Medicine
12:30-12:50pm	3:30-3:50pm	PANEL DISCUSSION	All speakers

Other Events of PBSS-San Francisco Bay:

2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus

2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies

2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals

2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices

2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)

2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices

2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics

2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6

2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies

2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices

2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA